By Greg Roumeliotis (Reuters) - Private equity firm Bain Capital stands to make more than 10 times the $250 million it invested in Cerevel Therapeutics Holdings Inc following the...
Investing.com -- Shares in Pfizer (NYSE:PFE) slumped in early trading on Friday after the drugmaker said that the twice-daily form of its new oral obesity treatment will not...
By Jonathan Stempel (Reuters) - Pfizer (NYSE:PFE) has been sued by Texas Attorney General Ken Paxton, who on Thursday accused the drugmaker of misrepresenting the efficacy of...
By Brendan Pierson (Reuters) -Texas Attorney General Ken Paxton accused Pfizer (NYSE:PFE) and its supplier Tris Pharma of providing children's ADHD medicine that it knew might...
By Ludwig Burger and Patricia Weiss FRANKFURT (Reuters) - Bayer (OTC:BAYRY)'s strategic review will consider a potentially tougher outlook for cash flows, its CEO said on Tuesday,...
Eli Lilly (NYSE:LLY)'s recent foray into the weight-loss market with the approval of its diabetes drug Mounjaro for weight management signals a strategic expansion for the...
By Bhanvi Satija and Savyata Mishra (Reuters) - Weight loss was the talk of this earnings season, making names such as Wegovy, Ozempic and Mounjaro the water-cooler discussion...
Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab). ELREFXIO is a targeted...
Pfizer Inc. (NYSE:PFE) today announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA)...